Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 93

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 1
Chunk 93
---
,750  
     192.7%
  
    Total other income (expense), net 
     (1,342,740) 
     5,126,230  
     (6,468,970) 
     (126.2)%
  
    Net loss 
     (15,379,641) 
     (8,976,315) 
     (6,403,326) 
     71.3%
  
    Deemed dividend on Series A, B and C Preferred Stock 
     (24,964,518) 
     -  
     (24,964,518) 
     100%
  
    Deemed dividend on Series D Preferred Stock 
     (6,649,828) 
     -  
     (6,649,828) 
     100%
  
    Deemed dividend related to Series C Common Warrants 
     (84,083) 
     -  
     (84,083) 
     100%
  
    Net loss attributable to common stockholders 
    $(47,078,070) 
    $(8,976,315) 
    $(38,101,755) 
     424.5%

Research and Development Expenses

Research and development
expenses were $8,048,000 for the nine months ended September 30, 2025 as compared to $6,157,000 for the nine months ended September 30,
2024, reflecting an increase of $1,891,000. The increase was primarily attributable to an increase in clinical expenses of $2,564,000,
an increase in scientific consulting fees of $706,000 and an increase in drug manufacturing costs of $276,000. In the first quarter of
2025, we began clinical trials related to the IND for CER-1236. This increase was primarily offset by a decrease in lab expenses of $481,000
primarily attributable to a decrease in toxicology studies performed in the 2025 period as compared to the 2024 period, a decrease in
research and development salaries and benefits of approximately $973,000 which included a decrease in stock-based compensation expense
of $775,000 primarily attributable to a decrease in accretion in stock-based option expense and a decrease in other development salaries
and benefits of $198,000, a decrease in depreciation expense of $120,000 and a decrease in other research and